CRMD

Business Context and Reporting Period

Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: CorMedix is a biopharmaceutical company focused on commercializing DefenCath, an FDA-approved antimicrobial catheter lock solution for patients with kidney failure receiving chronic hemodialysis. The product launched commercially in the U.S. inpatient setting in April 2024 and the outpatient setting in July 2024.

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held $66.3 million in cash and cash equivalents and $11.2 million in short-term investments. Management estimates sufficient liquidity to fund operations for at least twelve months.

Material Changes vs. Prior Period

• Revenue Generation: The company transitioned from zero revenue in Q1 2024 to $39.1 million in Q1 2025, driven by the commercial launch of DefenCath. Two customers accounted for 92% of total revenue (78% and 14%).
• Profitability: The company achieved a net income of $20.6 million in Q1 2025, a reversal from a net loss of $14.5 million in the prior year period. This was primarily due to gross profit from product sales offsetting operating expenses.
• Operating Expenses:
  • R&D: Increased 281% to $3.2 million due to ongoing clinical studies.
  • Selling & Marketing: Decreased 29% to $4.5 million following the severance of the internal sales force in early 2025 and the ramp-up of an outsourced force.
  • G&A: Increased 11% to $9.7 million, driven largely by non-cash stock-based compensation.
• Balance Sheet: Trade receivables increased by $3.0 million to $54.6 million, reflecting sales growth. Accrued expenses increased to $32.3 million, largely due to variable consideration reserves (rebates, chargebacks, returns).

Outlook, Risks, and Contingencies

• Guidance & Outlook: Management expects to fund operations for at least 12 months using existing cash, short-term investments, and commercial cash flows. Approximately $23.2 million remains available under the 2024 At-The-Market (ATM) equity program.
• Reimbursement: DefenCath has secured NTAP reimbursement for inpatient settings (extended through Nov 2026) and TDAPA reimbursement for outpatient dialysis settings (implemented July 2024). Pass-through status under OPPS was also confirmed for outpatient ambulatory settings.
• Legal Proceedings:
  • Securities Litigation: A consolidated class action lawsuit (In re CorMedix Inc. Securities Litigation) alleges violations related to NDA submissions and FDA communications. The company intends to vigorously contest the claims.
  • Derivative Litigation: Consolidated shareholder derivative actions alleging breaches of fiduciary duty are currently stayed pending the resolution of the class action motion to dismiss.
• Supply Chain: The company relies on a single FDA-approved source for taurolidine API and is working to secure 24 months of supply. An alternate supplier for heparin sodium is being qualified.
• Contractual Obligations: A three-year agreement with Syneos Health for an inpatient sales force commits the company to $9.1 million in minimum payments as of March 31, 2025.

Investor Verification Checklist

• Revenue Concentration: Verify the sustainability of revenue given that two customers represent 92% of Q1 2025 sales.
• Variable Consideration Reserves: Review the $27.8 million in accrued reserves for rebates, chargebacks, and returns, which significantly impacts net revenue recognition.
• ATM Program Utilization: Monitor the remaining $23.2 million capacity under the ATM program and potential dilution from future issuances.
• Legal Exposure: Track the status of the securities class action and derivative litigation, as unfavorable outcomes could result in significant costs.
• Supply Chain Security: Confirm progress on qualifying alternate suppliers for heparin sodium and securing long-term taurolidine API supply.